Jonathan Gardner
Senior Reporter | @ByJonGardner842 articles by Jonathan Gardner
-
FDA panel backs broader use of J&J, Bristol Myers cell therapies for myeloma
March 15, 2024 -
BIO changes stance, backs bill to limit China’s role in US biotech
March 14, 2024 -
FDA to focus on ‘early deaths’ in meeting on broader CAR-T use in myeloma
March 13, 2024 -
Roche, following setbacks, turns to its next Alzheimer’s drug
March 11, 2024 -
FDA delays decision on Lilly’s closely watched Alzheimer’s drug
March 8, 2024 -
Novo’s latest obesity pill spurs major weight loss in small trial
March 7, 2024 -
Alnylam, Roche blood pressure drug scores in second mid-stage trial
March 5, 2024 -
AstraZeneca’s drug pricing lawsuit dismissed by federal judge
March 4, 2024 -
Pfizer, looking for a jumpstart, leans into cancer drug research
March 1, 2024 -
Viking data suggest obesity drug could rival Zepbound, Wegovy
Feb. 27, 2024 -
Humira biosimilar from Alvotech, Teva wins FDA approval on third attempt
Feb. 26, 2024 -
Bavarian Nordic terminates cancer vaccine work
Feb. 21, 2024 -
Rick Gonzalez, longtime AbbVie CEO, to step down in July
Feb. 20, 2024 -
FDA to review expanded use of Sarepta Duchenne gene therapy
Feb. 16, 2024 -
BioAge raises $170M to back Phase 2-ready obesity drug
Feb. 13, 2024 -
CSL heart drug misses goal in large study
Feb. 12, 2024 -
Pharma CEOs, pressed by Senate panel, refuse to commit to price cuts
Feb. 8, 2024 -
Lilly sales surge on obesity, diabetes drug demand
Feb. 6, 2024 -
Novo Holdings to buy contract drugmaker Catalent for $16.5B
Feb. 5, 2024 -
Roche shuffles early stage pipeline as it joins obesity rush
Feb. 1, 2024 -
Novo resumes supplying starter doses of obesity drug Wegovy
Jan. 31, 2024 -
Gilead deepens investment in Arcus and TIGIT drugs
Jan. 30, 2024 -
Bristol Myers gets positive data in subcutaneous Opdivo trial
Jan. 29, 2024 -
EMA recommends earlier use of Bristol Myers cell therapy for multiple myeloma
Jan. 26, 2024 -
FDA orders new cancer warnings for CAR-T therapies
Jan. 23, 2024